166 related articles for article (PubMed ID: 35656035)
1. The Activity of Liposomal Linolenic Acid Against
Wang Y; Wu S; Wang L; Wang Y; Liu D; Fu Y; Xie Y
Front Cell Infect Microbiol; 2022; 12():865320. PubMed ID: 35656035
[No Abstract] [Full Text] [Related]
2. Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori.
Jung SW; Thamphiwatana S; Zhang L; Obonyo M
PLoS One; 2015; 10(3):e0116519. PubMed ID: 25793403
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.
Obonyo M; Zhang L; Thamphiwatana S; Pornpattananangkul D; Fu V; Zhang L
Mol Pharm; 2012 Sep; 9(9):2677-85. PubMed ID: 22827534
[TBL] [Abstract][Full Text] [Related]
4. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation.
Thamphiwatana S; Gao W; Obonyo M; Zhang L
Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17600-5. PubMed ID: 25422427
[TBL] [Abstract][Full Text] [Related]
5. The impact of liposomal linolenic acid on gastrointestinal microbiota in mice.
Li XX; Shi S; Rong L; Feng MQ; Zhong L
Int J Nanomedicine; 2018; 13():1399-1409. PubMed ID: 29563795
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.
Makobongo MO; Einck L; Peek RM; Merrell DS
PLoS One; 2013; 8(7):e68917. PubMed ID: 23935905
[TBL] [Abstract][Full Text] [Related]
7. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China.
Huang X; Liu Y; Lin Z; Wu B; Nong G; Chen Y; Lu Y; Ji X; Zhou X; Suo B; Chen Q; Wei J
PLoS One; 2021; 16(9):e0256225. PubMed ID: 34473713
[TBL] [Abstract][Full Text] [Related]
8. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland.
Karczewska E; Wojtas-Bonior I; Sito E; Zwolińska-Wcisło M; Budak A
Pharmacol Rep; 2011; 63(3):799-807. PubMed ID: 21857091
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates.
Hassan ST; Berchová K; Majerová M; Pokorná M; Švajdlenka E
Pharm Biol; 2016 Sep; 54(9):1736-40. PubMed ID: 26731378
[TBL] [Abstract][Full Text] [Related]
10. Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo.
Koga T; Inoue H; Ishii C; Okazaki Y; Domon H; Utsui Y
J Antimicrob Chemother; 2002 Jul; 50(1):133-6. PubMed ID: 12096020
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure.
Nestegard O; Moayeri B; Halvorsen FA; Tønnesen T; Sørbye SW; Paulssen E; Johnsen KM; Goll R; Florholmen JR; Melby KK
PLoS One; 2022; 17(4):e0265322. PubMed ID: 35442962
[TBL] [Abstract][Full Text] [Related]
12. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents.
Ogata SK; Godoy AP; da Silva Patricio FR; Kawakami E
J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):645-8. PubMed ID: 23403439
[TBL] [Abstract][Full Text] [Related]
13. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy.
Branca G; Spanu T; Cammarota G; Schito AM; Gasbarrini A; Gasbarrini GB; Fadda G
Int J Antimicrob Agents; 2004 Nov; 24(5):433-8. PubMed ID: 15519473
[TBL] [Abstract][Full Text] [Related]
14. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Gotoh A; Kawakami Y; Akamatsu T; Katsuyama T
Microbiol Immunol; 1997; 41(11):865-9. PubMed ID: 9444328
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan.
Cheng A; Sheng WH; Liou JM; Wang HP; Wu MS; Lin JT; Chang SC
J Microbiol Immunol Infect; 2015 Feb; 48(1):72-9. PubMed ID: 23036269
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole.
Blacky A; Makristathis A; Apfalter P; Willinger B; Rotter ML; Hirschl AM
Eur J Clin Microbiol Infect Dis; 2005 Apr; 24(4):276-9. PubMed ID: 15902535
[TBL] [Abstract][Full Text] [Related]
17. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
Miftahussurur M; Shrestha PK; Subsomwong P; Sharma RP; Yamaoka Y
BMC Microbiol; 2016 Nov; 16(1):256. PubMed ID: 27809767
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for
Miftahussurur M; Cruz M; Subsomwong P; Jiménez Abreu JA; Hosking C; Nagashima H; Akada J; Yamaoka Y
Am J Trop Med Hyg; 2017 May; 96(5):1050-1059. PubMed ID: 28193745
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.
Abouwarda AM; Ismail TA; Abu El-Wafa WM; Faraag AHI
World J Microbiol Biotechnol; 2022 Apr; 38(6):102. PubMed ID: 35486219
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.
Kamoda O; Anzai K; Mizoguchi J; Shiojiri M; Yanagi T; Nishino T; Kamiya S
Antimicrob Agents Chemother; 2006 Sep; 50(9):3062-9. PubMed ID: 16940102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
